BioMimetic Therapeutics' Clinical Investigator to Present Update of Orthopedic Clinical Results from U.S. and Canadian Trials; Company to host Conference Call on July 13 to Discuss Study Findings
Franklin, Tenn. – July 10, 2007 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that Sheldon Lin, M.D., one of the U.S. clinical investigators, will review follow-up results from ongoing U.S. and Canadian clinical trials evaluating GEM OS®1 Bone Graft in foot and ankle fusion indications. Dr. Lin's presentation is scheduled for July 13, 2007 at 9:25 a.m. EDT at the American Orthopedic Foot and Ankle Society Meeting (AOFAS) which is being held in Toronto, Canada. The Company will host a conference call to discuss the study's findings at 12:00 p.m. EDT the same day. Members of management and Dr. Lin will participate in the call which will include a brief Q&A session.
The conference call can be accessed by dialing 866-356-4441 (passcode 82199928) on July 13. The international dial in number is 617-597-5396. The same passcode applies. Participants should dial in 15 minutes prior to the 12:00 p.m. call. A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS®1 and GEM OS®2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of BioMimetic. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. There are many important factors that could cause actual results to differ materially from those indicated in the forward-looking statements. BioMimetic's actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with the marketing of BioMimetic's product and product candidates, unproven preclinical and clinical development activities, regulatory oversight and approval, and other risks detailed in the company's filings with the Securities and Exchange Commission. Except as required by law, BioMimetic undertakes no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for changes made to this document by wire services or Internet services.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
